News
Displaying 111–120 of 508
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
Research NewsThe LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Your Dollar Makes a Difference
Foundation NewsAt the Foundation Fighting Blindness, a dollar is more than just a dollar – it’s a path to transforming lives. But just where does your donation go?
-
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
Research NewsThe company is seeking a partner to move the LCA10 program forward
-
Foundation News
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential therapies.
-
In the Press
On World Sight Day 2022, Retina International is presenting data from a report on its study into the Socio-economic Impact of late-stage age-related macular degeneration (AMD) in Bulgaria, Germany, and USA.
-
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Research NewsReports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Research News
Small data sets present challenges for developing rare disease AI tools
.png)
.png)
